STEM CELL THERAPEUTIC

The only Korean company invited to North American Rare Medicine conference

Administration of lung disease medicine ‘PNEUMOSTEM’ in clinical trial completed

Administration of lung disease medicine ‘PNEUMOSTEM’ started in U.S. clinical trial

Accumulated Dosage of CARTISTEM Exceeds 2,000 Cases

Nikkei Japan Reports the Status of MEDIPOST’s Stem Cell Research

43% Increase in Dosage of CARTISTEM, for 4th Quarter of 2014 Year on Year

MEDIPOST will set up a joint venture company in China

Korean stem cells regenerate coach Hiddink’s worn-out knee cartilage

Lung disease stem cell treatment drug ‘PNEUMOSTEM’ application for US clinical trial

Lung disease stem cell drug designated ‘orphan drug in development stage’

Stem Cell Drug ‘CARTISTEM’ Treatment Japanese Patent

US patent for ‘CARTISTEM’ raw material stem cell differentiation capability selection technology